Amantadine: an antiviral and antiparkinsonian agent
نویسندگان
چکیده
Amantadine is an antiviral agent that specifically inhibits influenza A virus replication at a micromolar concentration. This drug is also very effective in the treatment of human Parkinson’s disease. Other important clinical applications of this agent have been studied recently, ranging from viral infections, e.g. herpes, herpes zoster neuralgia to granulomatosis and from neuroleptic extrapyramidal movement disease to depression and cocain dependence. Biological and pharmacological activities of amantadine presented in this paper are focused on the explanation of the mechanism of amantadine antiviral and antiparkinsonian effects and on general use of this agent in medicine.
منابع مشابه
The Use of Amantadine in Parkinson’s Disease and other Akinetic-Rigid Disorders
Introduction Amantadine was originally introduced as an antiviral agent to treat influenza A and was coincidentally found to ameliorate symptoms in a patient with Parkinson’s Disease (PD) in 1969. Since that time many clinical trials have investigated the efficacy of amantadine alone and in combination with other antiparkinsonian drugs. Most of these trials took place in the early 1970s. More r...
متن کاملInhibition of West Nile Virus Multiplication in Cell Culture by Anti-Parkinsonian Drugs
West Nile virus (WNV) is a mosquito-borne flavivirus maintained in a transmission cycle between mosquitoes and birds, but it can also infect other vertebrates, including humans, in which it can cause neuroinvasive diseases. To date, no licensed vaccine or therapy for human use against this pathogen is yet available. A recent approach to search for new antiviral agent candidates is the assessmen...
متن کاملThe noradrenaline transporter as site of action for the anti-Parkinson drug amantadine.
Amantadine is an established antiparkinsonian drug with a still unclear molecular site of action. In vivo studies on rodents, in vitro studies on tissue of rodents as well as binding studies on post mortem human tissue implicate monoamine transporters and NMDA receptors. In order to re-examine its action at human variants of these proteins on intact cells we established cells stably expressing ...
متن کاملLevetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Levetiracetam (LEV) (Keppra; UCB Pharma, Brussels, Belgium) has recently been reported to have antidyskinetic activity against levodopa (L-DOPA)-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset and macaque models of Parkinson's disease. Amantadine is frequently used as adjunctive therapy for L-DOPA-induced dyskinesia, but adverse effects limit its ...
متن کاملTrends in Antiparkinsonian Medication Use in New Zealand: 1995–2011
Prescribing trends for medications are influenced by development of new drugs, changes in knowledge about efficacy and side effects, and priorities set by funding agencies. Changes in the utilization of antiparkinsonian agents in the outpatient community in New Zealand were investigated by using the national prescription database for the period 1995-2011. The dispensed volumes of antiparkinsoni...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2002